Selective and potent raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth

Molecular Cancer Therapeutics

Volumn 9, Issue 8, 2010, Pages 2399-2410

  Carnahan, Josette ^a   Beltran, Pedro J ^a   Babij, Carol ^a   Le, Quynh ^a   Rose, Mark J ^a   Vonderfecht, Steven ^a   Kim, Joseph L ^a   Smith, Adrian L ^a   Nagapudi, Karthik ^a   Broome, Martin A ^a   Fernando, Manory ^a   Kha, Hue ^a   Belmontes, Brian ^a   Radinsky, Robert ^a   Kendall, Richard ^a   Burgess, Teresa L ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N [5 (3 DIMETHYLAMINOBENZAMIDO) 2 METHYLPHENYL] 4 HYDROXYBENZAMIDE; RAF PROTEIN; SMALL INTERFERING RNA; SORAFENIB; UO 126;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; MUTANT; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR; TUMOR GROWTH; TUMOR XENOGRAFT; WILD TYPE;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; EPITHELIUM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERPLASIA; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOENZYMES; MAP KINASE SIGNALING SYSTEM; MICE; MUTANT PROTEINS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955475709     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0181     Document Type: Article

References (43)

1. Leicht DT, Balan V, Kaplun A, et al. Raf kinases: function, regulation and role in human cancer. Biochim Biophys Acta 2007;1773:1196-212. (Pubitemid 47161035)
2. Shaul YD, Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta 2007;1773:1213-26.
3. Wojnowski L, Zimmer AM, Beck TW, et al. Endothelial apoptosis in Braf-deficient mice. Nat Genet 1997;16:293-7.
4. Wojnowski L, Stancato LF, Zimmer AM, et al. Craf-1 protein kinase is essential for mouse development. Mech Dev 1998;76:141-9.
5. Wojnowski L, Stancato LF, Larner AC, Rapp UR, Zimmer A. Overlapping and specific functions of Braf and Craf-1 proto-oncogenes during mouse embryogenesis. Mech Dev 2000;91:97-104. (Pubitemid 30125909)
6. Marais R, Light Y, Paterson HF, Mason CS, Marshall CJ. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem 1997;272:4378-83. (Pubitemid 27078513)
7. Wiese S, Pei G, Karch C, et al. Specific function of B-Raf in mediating survival of embryonic motoneurons and sensory neurons. Nat Neurosci 2001;4:137-42. (Pubitemid 32125257)
8. Mercer K, Chiloeches A, Huser M, Kiernan M, Marais R, Pritchard C. ERK signalling and oncogene transformation are not impaired in cells lacking A-Raf. Oncogene 2002;21:347-55. (Pubitemid 34123797)
9. Pritchard CA, Bolin L, Slattery R, Murray R, McMahon M. Post-natal lethality and neurological and gastrointestinal defects in mice with targeted disruption of the A-Raf protein kinase gene. Curr Biol 1996;6:614-7. (Pubitemid 126656319)
10. Pritchard CA, Samuels ML, Bosch E, McMahon M. Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells. Mol Cell Biol 1995;15:6430-42.
11. Bosch E, Cherwinski H, Peterson D, McMahon M. Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A-Raf and Raf-1. Oncogene 1997;15:1021-33.
12. Sharma PS, Sharma R, Tyagi T. Receptor tyrosine kinase inhibitors as potent weapons in war against cancers. Curr Pharm Des 2009;15:758-76.
13. Thompson N, Lyons J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 2005;5:350-6.
14. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26:3291-310.
15. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
16. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004;5:875-85. (Pubitemid 39486539)
17. Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001;8:219-25.
18. King AJ, Patrick DR, Batorsky RS, et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res 2006;66:11100-5.
19. Ramurthy S, Subramanian S, Aikawa M, et al. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase Inhibitors. J Med Chem 2008;51:7049-52.
20. Tsai J. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 2008;105:3041-6.
21. Hoeflich KP, Herter S, Tien J, et al. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogenactivated protein kinase pathway suppression. Cancer Res 2009;69:3042-51.
22. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439:358-62.
23. Flaherty K, Puzanov I, Sosman J, et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009;27:15S; abstr 9000.
24. Puzanov I, Nathanson KL, Chapman PB, et al. PLX4032, a highly selective V600EBRAF kinase inhibitor: clinical correlation of activity with pharmacokinetic and pharmacodynamic parameters in a phase I trial. J Clin Oncol 2009;27:15s; abstr 9021.
25. Smith AL, DeMorin FF, Paras NA, et al. Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline. J Med Chem 2009;52:6189-92.
26. Van Gompel JJ, Kunnimalaiyaan M, Holen K, Chen H. ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Mol Cancer Ther 2005;4:910-7. (Pubitemid 40909073)
27. Kappes A, Vaccaro A, Kunnimalaiyaan M, Chen H. ZM336372, a Raf-1 activator, inhibits growth of pheochromocytoma cells. J Surg Res 2006;133:42-5.
28. Houben R, Ortmann S, Schrama D, et al. Activation of the MAP kinase pathway induces apoptosis in the Merkel cell carcinoma cell line UISO. J Invest Dermatol 2007;127:2116-22.
29. Mueller BM, Romerdahl CA, Trent JM, Reisfeld RA. Suppression of spontaneous melanoma metastasis in scid mice with an antibody to the epidermal growth factor receptor. Cancer Res 1991;51:2193-8.
30. Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE. Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res 1981;41:1751-6.
31. Giard DJ, Aaronson SA, Todaro GJ, et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 1973;51:1417-23.
32. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81. (Pubitemid 46316032)
33. Duncia JV, Santella JB III, Higley CA, et al. MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg Med Chem Lett 1998;8:2839-44.
34. Hall-Jackson CA, Eyers PA, Cohen P, et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol 1999;6:559-68.
35. Santos SDM, Verveer PJ, Bastiaens PIH. Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate. Nat Cell Biol 2007;9:324-30.
36. Yen I, Song K, Stokoe S, et al. Understanding the effects of RAF inhibitors on RAF signaling in B-RAF V600E mutant versus wild type tumors. Mol Cancer Ther 2009:B90.
37. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;140:209-21.
38. Hatzivassiliou G, Song K, Yen Y, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, doi: 10.1038/nature08833.
39. Carnahan J, Beltran P, Babij C, et al. Selective and potent inhibitors of the mutant B-Raf pathway paradoxically stimulate the MAPK pathway in wild-type B-Raf cells. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research. Washington (DC):2010, p. Abstr #21.
40. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009;60:299-305.
41. Beldner M, Jacobson M, Burges GE, Dewaay D, Maize JC, Jr., Chaudhary UB. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. Oncologist 2007;12:1178-82.
42. Hong DS, Reddy SB, Prieto VG, et al. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol 2008;144:779-82.
43. Poulikakos P, Joseph E, Tsai J, Bollag G, Rosen N. The RAF inhibitor PLX4032 effectively suppresses MAPK signaling in cells harboring mutant BRAF, but not in cells with upstream activation of the pathway. AACR Meeting Abstracts 2008 April 12, 2008;2008:5800.